Accordingly, differential expression analyses revealed that many surface markers that distinguish the different AML states also mark their corresponding healthy counterparts, such as CD133 for immature AMLs or CD14 and CD11b for monocytic AMLs (Fig. 4g). Here, PROM1 is linked to acute myeloid leukemia.